Introduction
Gastrointestinal stromal tumors (GISTs) represent a diverse group of rare mesenchymal tumors predominantly arising in the gastrointestinal tract. Among these, the succinate dehydrogenase (SDH)-deficient subtype accounts for approximately 5% to 7.5% of all GIST cases, primarily affecting adolescents and young adults. These tumors demonstrate inherent resistance to standard tyrosine kinase inhibitors (TKIs) like imatinib, historically resulting in a median progression-free survival (PFS) of just 6 to 10 months with conventional therapies. Recent advances led by Professor Ruihua Xu and colleagues at Sun Yat-sen University have unveiled promising therapeutic avenues with the novel multikinase inhibitor olverembatinib, offering new hope for these difficult-to-treat tumors.
